Stay updated on Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant changes, including the addition of new drug names and a revision of the study version. Notably, the detailed description of the Phase 1b study for pancreatic adenocarcinoma has been removed, which may impact the understanding of the study's purpose and methodology.SummaryDifference38%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check88 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check95 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial page.